Patient Enrollment completed in Ph 3 Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent HCC March 11, 2025
ENHERTU Demonstrated Statistically Significant and Clinically Meaningful OS Improvement in Patients with HER2+ve Metastatic Gastric Cancer at Interim Analysis of DESTINYGastric04 Ph 3 Trial March 11, 2025
TEVIMBRA Approved in U.S. for 1L Treatment of Advanced ESCC in Combination with Chemotherapy March 11, 2025
Enrollment Completed in Ph 2 Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China March 11, 2025
Imfinzi-based regimen demonstrated statistically significant and clinically meaningful EFS improvement in resectable early-stage G/GEJ cancers March 11, 2025
Positive Topline Ph 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Grade 1/2 SSTR+ve GEP-NETs Presented March 11, 2025
European Commission Approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with Unresectable or Advanced HCC March 11, 2025
FDA accepts Supplemental BLA for Opdivo + Yervoy for Patients with Unresectable or Metastatic MSI-H or MRD CRC March 4, 2025
First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer March 4, 2025
Positive Final Survival Data from Ph 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Announced March 4, 2025
GEMSTONE-303 article published in JAMA, highlighting efficacy of sugemalimab + CAPOX vs placebo + CAPOX as 1L treatment for patients with unresectable locally advanced/metastatic G/GEJ adenocarcinoma with PD-L1 CPS ≥5 March 4, 2025
FDA RMAT Designation for CAR-NK in Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer March 4, 2025
Investigator Initiated Ph 2 Trial for Neoadjuvant Muzastotug (ADG126) in CRC Announced February 28, 2025
Go-ahead obtained to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review February 25, 2025
Fast Track Designation granted from the U.S. FDA for Amezalpat to Treat Patients with HCC February 19, 2025
Progress and Expansion of Clinical Collaboration Program for ADG126 (muzastotug) + KEYTRUDA combo in MSS CRC announced February 10, 2025
BRAFTOVI Combination Regimen Significantly Improved PFS and OS in Ph 3 BREAKWATER Trial February 5, 2025
Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study of sirexatamab (DKN-01) Reported February 4, 2025
Positive Topline Results of Ph 3 COMPETE Trial with ITM-11 in Patients with Gr 1 or 2 GEP-NETs announced February 4, 2025
